doctor pbm glp-1 approval process PBMs Help Expand Access and Affordability for GLP‑1 Medications The Landscape Of GLP-1 Receptor

Description

elife

The company has acquired a European competitor, Zava, which already has 1.3 million customers for a range of productsincluding some obesity treatmentsin the UK, Ireland, Germany and France

For GLP-1 Users: GLP-1 medications actively slow gastric emptying, frequently leading to stubborn constipation

The August 2023 announcement of topline results was followed in November 2023 by a presentation of detailed results7, which revealed a statistically significant reduction in non-fatal myocardial infarction of 28% and smaller reductions in cardiovascular death and non-fatal stroke which were not statistically significant over the length of the trial (up to five years)